It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Details
Title
Publisher Correction: Epigenomic analysis reveals a unique DNA methylation program of metastasis-competent circulating tumor cells in colorectal cancer
Author
Bao-Caamano, Aida 1 ; Costa-Fraga, Nicolás 2 ; Cayrefourcq, Laure 3 ; Jácome, María Amalia 4 ; Rodriguez-Casanova, Aitor 5 ; Muinelo-Romay, Laura 6 ; López-López, Rafael 7 ; Alix-Panabières, Catherine 8 ; Díaz-Lagares, Angel 9
1 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645)
2 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058)
3 University Medical Center of Montpellier, IURC, Laboratory of Rare Human Circulating Cells, Montpellier Cedex 5, France (GRID:grid.411720.1) (ISNI:0000 0004 0623 3948); CREEC, MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
4 Universidade da Coruña, Department of Mathematics, MODES Group, CITIC, Faculty of Science, A Coruña, Spain (GRID:grid.8073.c) (ISNI:0000 0001 2176 8535)
5 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Health Research Institute of Santiago (IDIS), Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058)
6 Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Health Research Institute of Santiago de Compostela (IDIS), Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058)
7 Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Health Research Institute of Santiago (IDIS), Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058); University Clinical Hospital of Santiago (CHUS/SERGAS), Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945)
8 University Medical Center of Montpellier, IURC, Laboratory of Rare Human Circulating Cells, Montpellier Cedex 5, France (GRID:grid.411720.1) (ISNI:0000 0004 0623 3948); CREEC, MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141); European Liquid Biopsy Society (ELBS), Hamburg, Germany (GRID:grid.121334.6)
9 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058); University Hospital Complex of Santiago de Compostela (CHUS), Department of Clinical Analysis, 15706 Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945)
1 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645)
2 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058)
3 University Medical Center of Montpellier, IURC, Laboratory of Rare Human Circulating Cells, Montpellier Cedex 5, France (GRID:grid.411720.1) (ISNI:0000 0004 0623 3948); CREEC, MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141)
4 Universidade da Coruña, Department of Mathematics, MODES Group, CITIC, Faculty of Science, A Coruña, Spain (GRID:grid.8073.c) (ISNI:0000 0001 2176 8535)
5 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Health Research Institute of Santiago (IDIS), Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058)
6 Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Health Research Institute of Santiago de Compostela (IDIS), Liquid Biopsy Analysis Unit, Translational Medical Oncology Group (ONCOMET), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058)
7 Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Health Research Institute of Santiago (IDIS), Roche-Chus Joint Unit, Translational Medical Oncology Group (ONCOMET), Santiago de Compostela, Spain (GRID:grid.488911.d) (ISNI:0000 0004 0408 4897); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058); University Clinical Hospital of Santiago (CHUS/SERGAS), Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945)
8 University Medical Center of Montpellier, IURC, Laboratory of Rare Human Circulating Cells, Montpellier Cedex 5, France (GRID:grid.411720.1) (ISNI:0000 0004 0623 3948); CREEC, MIVEGEC, University of Montpellier, CNRS, IRD, Montpellier, France (GRID:grid.121334.6) (ISNI:0000 0001 2097 0141); European Liquid Biopsy Society (ELBS), Hamburg, Germany (GRID:grid.121334.6)
9 University Clinical Hospital of Santiago (CHUS/SERGAS), Epigenomics Unit, Cancer Epigenomics, Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945); Universidade de Santiago de Compostela (USC), Galician Precision Oncology Research Group (ONCOGAL), Medicine and Dentistry School, Santiago de Compostela, Spain (GRID:grid.11794.3a) (ISNI:0000 0001 0941 0645); Centro de Investigación Biomédica en Red Cáncer (CIBERONC), ISCIII, Madrid, Spain (GRID:grid.510933.d) (ISNI:0000 0004 8339 0058); University Hospital Complex of Santiago de Compostela (CHUS), Department of Clinical Analysis, 15706 Santiago de Compostela, Spain (GRID:grid.411048.8) (ISNI:0000 0000 8816 6945)
Pages
16999
Publication year
2023
Publication date
2023
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2874659446
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.